

## For Immediate Release

# The Trendlines Group Establishes Two New Companies

The Trendlines Group's Israel-based Trendlines Medical incubator has established two new companies.

**Misgav, Israel – 15 December 2015** – In keeping with its mission to create and develop medical and agricultural technologies companies to improve the human condition, The Trendlines Group Ltd (“**Trendlines**” or the “**Company**” and together with its subsidiaries and associated companies, the “**Group**”) (SGX:42T) announced today that it has, via Trendlines Medical – Misgav Ltd. established two new portfolio companies, namely Tandem Technologies Ltd. (“**Tandem Technologies**”) and Zeev Implants Ltd. (“**Zeev Implants**”) (“**Establishment of Portfolio Companies**”). Subsequent to the aforementioned, the number of Trendlines’ portfolio companies has increased to 47.

The two medical companies are in the gastroenterology and dental markets. Tandem Technologies is in the business of developing a unique device for more efficient removal and retrieval of polyps in the colon, while Zeev Implants is in the business of developing a modular dental implant.

Founded by medtech entrepreneur and Tandem Technologies' chief executive officer, Noam Hassidov, Tandem Technologies aims to make the process of removing and retrieving colon polyps much more efficient and accurate, with the goal of a near 100% retrieval rate. The technology is based on proven solutions in gastroenterology. Trendlines has subscribed for a 48.8% fully-diluted share in Tandem Technologies.

Zeev Implants was founded by Zeev Implants' chief executive officer, Pinchas Kfir, a dental surgeon, lawyer, and experienced businessperson. Zeev Implants' modular dental implant technology is intended to solve the most common sources of dental implant problems and diseases, including peri-implant disease, without the need to remove or replace the implant. The special implant can be integrated into existing implants. Patented in Israel, patents are pending in the United States and Europe. Trendlines has subscribed for a 49.8% fully-diluted share in Zeev Implants.

Details on the Company's business model can be found on pages 167 to 175 of the offer document dated 16 November 2015.

- End -

### **About The Trendlines Group Ltd.**

The Group focuses on developing technology-based companies in the medical and agricultural fields. The Group creates and develops companies in accordance with its mission to improve the human condition. To this end, the Group discovers, invests in, incubates and provides services to life sciences companies in the fields of medical and agricultural technologies.

---

For more information, please contact the IR representatives of The Trendlines Group in Singapore:

Romil SINGH / Reyna MEI

[romil@financialpr.com.sg](mailto:romil@financialpr.com.sg) / [reyna@financialpr.com.sg](mailto:reyna@financialpr.com.sg)

Tel: (65) 6438 2990, Fax: (65) 6438 0064

---

The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGXST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.